Phase 3 N=465 Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery
General Anesthesia
Primary: Success Rate of General Anesthesia Induction — 298; 143 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=34 A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
Idiopathic Thrombocytopenic Purpura
Primary: Achievement Rate of Stable Platelet Response — 36.4; 0.0 Percentage of participants — p=0.030
Phase 3 N=359 Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma
Asthma
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) — 0.078; 0.136 Liters
Phase 3 N=257 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
Diabetes Type 2 · Diabetes Mellitus · Glucose Metabolism Disorders
Primary: Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg]) — -26.1; -25.9; -9.96 millimoles per mole (mmol/mol) — p=<0.001
Phase 3 N=681 A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Primary: SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 29.7; 10.2; 5.5; 0.4 Percentage of Participants
Phase 3 N=199 Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
Hemorrhagic Shock · Acute Blood Loss Anemia · Traumatic Brain Injury
Primary: Packed Red Blood Cells Equivalents Units Transfused (1 Whole Blood Unit Treated as 1 Packed Red Blood Cell Unit and 1 Fresh Frozen Plasma Unit) — 3.8; 5.7 units
Phase 3 N=669 Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
Prostatic Neoplasms
Primary: Radiological Progression-free Survival (rPFS) Assessed by Central Review — NA; 25.0 Months — p=<0.0001
Phase 3 N=795 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
Type 2 Diabetes · T2D
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] — -1.19; -1.16 Percentage of HbA1c
Phase 3 N=124 Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
C3G · IC-MPGN · C3 Glomerulopathy
Primary: Randomized Controlled Period: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio (uPCR) at Week 26 — -1.114; 0.029 log (uPCR) — p=<0.0001
Phase 3 N=1,153 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Atopic Dermatitis
Primary: Primary Treatment Period: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events — 2.1; 4.5 percentage of participants
Phase 3 N=184 A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
Lymphoma, Non-Hodgkin
Primary: Event-free Survival (EFS) Per Independent Review Committee (IRC) — 2.4; 29.5 Months
Phase 3 N=137 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Phase 3 N=2,516 A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma
Asthma
Primary: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) — 62; 110 Participants — p=<0.001
Phase 3 N=518 Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Survival — 8.31; 8.51 Months
Phase 3 N=1,075 Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
Acute Pain
Primary: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo — 70.6…